Advanced Non Squamous NSCLC Clinical Trial
Official title:
A Single-Arm Phase II Trial of Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy
| NCT number | NCT04670913 |
| Other study ID # | NCC2607 |
| Secondary ID | |
| Status | Recruiting |
| Phase | Phase 2 |
| First received | |
| Last updated | |
| Start date | June 28, 2021 |
| Est. completion date | June 2022 |
The purpose of this study is to assess the efficacy and safety of Camrelizumab plus Apatinib in the treatment of advanced non-squamous NSCLC previously treated with first-line immunotherapy
| Status | Recruiting |
| Enrollment | 30 |
| Est. completion date | June 2022 |
| Est. primary completion date | December 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility | Inclusion Criteria: 1. Provision of signed (infomed consent form, ICF). 2. The best response of first-line immunotherapy was SD or above, and PFS was at least 3 months. 3. Male and female aged =18 years and =75 years. 4. Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent or progressive disease following multimodal therapy. 5. Patients who are unwilling to receive chemotherapy after disease recurrence or progression during/after first-line treatment including PD-(L)1 combined with chemotherapy, and PD-(L)1 monotherapy for advanced or metastatic disease. 6. Measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria. 7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 8. Subjects are eligible if CNS metastases are asymptomatic or treated. 9. Life expectancy =12 weeks. 10. Fertile female must agree to use adequate contraception within 24 weeks from the beginning of the first dose of study medication to the last dose. 11. Adequate organ and marrow function. Exclusion Criteria: 1. Prior treatment with anti-tumor virus, or prior T cell co-stimulation factors,including anti-Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody or other T cell-targeted drugs. 2. Subjects who had discontinued prior treatment due to immune-related adverse events (irAEs) or who are not suitable for PD-(L)1 treatment assessed by the investigator. 3. Subjects with histologically or cytologically-documented squamous cell NSCLC. 4. Prior treatments with anti-angiogenic agents. 5. Subjects with activated EGFR gene mutation or ALK fusion mutation. 6. Untreated or active central nervous system metastases (such as brain or meningeal metastases). Subjects are eligible if CNS metastases are asymptomatic or treated and subjects are off corticosteroids for at least 2 weeks prior to first dose of study therapy. 7. Radiotherapy for the chest and whole brain should be completed within 4 weeks before the first dose of study drug (palliative radiotherapy for bone lesions should be completed before the first dose of study drugs). 8. History of active or recent history of known or suspected autoimmune disease. 9. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, radiation pneumonitis requiring steroid therapy, or evidence of active pneumonitis with clinical symptoms. 10. History of active tuberculosis regardless of prior treatment. 11. Malignancies other than NSCLC within 5 years prior to first administration of drugs, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome, such as cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and ductal carcinoma in situ after radical resection. 12. Known mental illness, alcohol abuse, inability to quit smoking, drug or drug abuse, etc. 13. Active hepatitis B or hepatitis C; History of known HIV-positive history or known AIDS. 14. Treatment with any investigational agent within 28 days of signing ICF. 15. According to the judgment of the investigator, subjects have other factors that may cause the study to be terminated halfway, such as non-compliance with the protocol, other serious diseases (including mental illness) requiring combined treatment, severe laboratory abnormalities, and Factors such as family or society will affect the safety of subjects or the collection of data and samples. |
| Country | Name | City | State |
|---|---|---|---|
| China | China | Beijing | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Junling Li |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Progression-free Survival (PFS) | PFS is determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). | up to 1 year | |
| Secondary | Objective response rate (ORR) | ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR:
Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 by investigator. |
up to 1 year | |
| Secondary | Duration of Response | Duration of Response, determined using RECIST v1.1 criteria | up to 1 year | |
| Secondary | Disease Control Rate (DCR) | Disease Control Rate, determined using RECIST v1.1 criteria | up to 1 year | |
| Secondary | Overall Survival (OS) | Overall survival is the time interval from the date of randomization to death due to any reason or lost of follow-up | up to 2 years | |
| Secondary | Adverse Events (AEs) and Serious Adverse Events(SAEs) | The number of participants experiencing an AE and SAE will be assessed.Adverse | up to 1 year | |
| Secondary | QLQ-LC13 | Quality of Life questionnaire lung cancer module 13 | up to 1 years | |
| Secondary | EORTCQLQ-C30 | European Organization for Reasearch and Treatment of Cancer C30 | up to 1 years |